Immunotherapy: An Effective Frontier in Alzheimer’s and Parkinson’s Treatment
At NURAVAX, we believe in the power of immunotherapy as a groundbreaking approach to treat Alzheimer’s and Parkinson’s diseases. Our focus is on developing vaccines to stimulate the body's own immune response against key pathological factors: beta-amyloid, tau proteins, and a-synuclein.
Targeted Antibody Response: Our vaccines are designed to induce antibodies that actively target and reduce the harmful effects of Abeta, tau, and a-syn.
Preventing Pathological Progression: By forming antigen-antibody complexes within the brain, our approach helps prevent the aggregation and further spread of these pathological molecules. This stops them from binding together to form harmful structures like oligomers, plaques, and tangles.
Eliminating Pathological Agents: Once these harmful molecules are bound by antibodies, they are transferred from the brain into the peripheral circulation. Here, they are effectively identified and eliminated by the body’s immune system.